Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: LOW stock price vs BNTX: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at BNTX's multiple
Needs BNTX P/E.
Implied fair value · at LOW's multiple
Needs Annual EPS is negative, LOW P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Ten period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
USD conversion input: 1 EUR = 1.155100 USD. FX date unavailable.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
LOWES COMPANIES INC · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
BioNTech SE · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
HOME DEPOT, INC.
LOW vs HD
SHERWIN WILLIAMS CO
LOW vs SHW
WILLIAMS SONOMA INC
LOW vs WSM
Tractor Supply Company
LOW vs TSCO
Moderna, Inc.
LOW vs MRNA
GILEAD SCIENCES, INC.
LOW vs GILD
AMGEN INC
LOW vs AMGN
REGENERON PHARMACEUTICALS, INC.
LOW vs REGN
INCYTE CORP
LOW vs INCY
VERTEX PHARMACEUTICALS INC / MA
LOW vs VRTX
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Edwyn research
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe LOW should be valued closer to its BNTX-implied sales multiple despite its already-fair historical trading range, then consider a selective bullish stance because the operating business is profitable and materially stronger than BNTX on margins and leverage; otherwise, the DCF and historical-band checks argue for restraint.
The comparison shows a very large valuation disconnect: the provided BNTX-implied price is $1,162.00 versus LOW's current price of $227.46, implying 410.9% upside. However, LOW already trades within its historical band and well above the DCF range, which suggests the modeled upside depends heavily on an aggressive relative-multiple assumption rather than a broad cross-check.
Supporting Metrics
